Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: Early single-center experience.
作者信息
Dhand Abhay, Lobo Stephen A, Wolfe Kevin, Feola Nicholas, Nabors Christopher
机构信息
Department of Medicine, Westchester Medical Center, NY, USA.
Department of Surgery, Westchester Medical Center, NY, USA.
出版信息
Clin Transplant. 2021 Apr;35(4):e14245. doi: 10.1111/ctr.14245. Epub 2021 Feb 17.
Abstract
摘要
相似文献
1
Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: Early single-center experience.
Clin Transplant. 2021 Apr;35(4):e14245. doi: 10.1111/ctr.14245. Epub 2021 Feb 17.
2
A Programmatic Response, Including Bamlanivimab or Casirivimab-imdevimab Administration, Reduces Hospitalization and Death in COVID-19 Positive Abdominal Transplant Recipients.
Transplantation. 2022 Feb 1;106(2):e153-e157. doi: 10.1097/TP.0000000000003953.
3
Casirivimab-imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: An Early Experience.
Transplantation. 2021 Jul 1;105(7):e68-e69. doi: 10.1097/TP.0000000000003737.
4
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.
Am J Transplant. 2020 Jul;20(7):1800-1808. doi: 10.1111/ajt.15941. Epub 2020 May 10.
5
Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients.
Transpl Infect Dis. 2021 Oct;23(5):e13662. doi: 10.1111/tid.13662. Epub 2021 Jun 16.
6
Sotrovimab for Treatment of COVID-19 in Solid Organ Transplant Recipients.
Transplantation. 2022 Jul 1;106(7):e336-e337. doi: 10.1097/TP.0000000000004136. Epub 2022 Apr 15.
7
Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
Transpl Infect Dis. 2022 Aug;24(4):e13901. doi: 10.1111/tid.13901. Epub 2022 Jul 25.
8
Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge.
Am J Transplant. 2022 Oct;22(10):2458-2463. doi: 10.1111/ajt.17098. Epub 2022 May 30.
9
Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience.
Transplantation. 2022 Jul 1;106(7):e343-e345. doi: 10.1097/TP.0000000000004150. Epub 2022 Mar 24.
10
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
Front Immunol. 2021 Dec 9;12:790469. doi: 10.3389/fimmu.2021.790469. eCollection 2021.
引用本文的文献
1
Sotrovimab in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis.
Korean J Transplant. 2023 Dec 31;37(4):277-285. doi: 10.4285/kjt.23.0038. Epub 2023 Nov 3.
2
The Treatment of COVID-19 With Monoclonal Antibody Therapy: Patient-Reported Outcomes.
Cureus. 2022 Sep 16;14(9):e29247. doi: 10.7759/cureus.29247. eCollection 2022 Sep.
3
Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies.
Transpl Int. 2022 Oct 4;35:10721. doi: 10.3389/ti.2022.10721. eCollection 2022.
4
Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?
Viruses. 2022 Aug 24;14(9):1860. doi: 10.3390/v14091860.
5
Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients.
Kidney Int Rep. 2022 Jun;7(6):1241-1247. doi: 10.1016/j.ekir.2022.03.020. Epub 2022 Mar 26.
6
Durable Protection after Anti-SARS-CoV-2 Monoclonal Antibody Therapy.
Kidney360. 2022 Jan 27;3(1):8-10. doi: 10.34067/KID.0007722021.
7
Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
Hematol Oncol. 2022 Apr;40(2):280-286. doi: 10.1002/hon.2974. Epub 2022 Feb 17.
8
COVID-19 and Solid Organ Transplantation: Role of Anti-SARS-CoV-2 Monoclonal Antibodies.
Curr Transplant Rep. 2022;9(1):26-34. doi: 10.1007/s40472-022-00357-2. Epub 2022 Jan 15.
9
The Role of HLA Antigens and Steroid Dose on the Course of COVID-19 of Patients After Kidney Transplantation.
Front Med (Lausanne). 2021 Nov 1;8:730156. doi: 10.3389/fmed.2021.730156. eCollection 2021.
10
Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region.
J Clin Med. 2021 Oct 13;10(20):4682. doi: 10.3390/jcm10204682.
本文引用的文献
1
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
N Engl J Med. 2021 Mar 11;384(10):905-914. doi: 10.1056/NEJMoa2033130. Epub 2020 Dec 22.
2
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
N Engl J Med. 2021 Jan 21;384(3):229-237. doi: 10.1056/NEJMoa2029849. Epub 2020 Oct 28.
3
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.
Am J Transplant. 2020 Jul;20(7):1800-1808. doi: 10.1111/ajt.15941. Epub 2020 May 10.
Zotero 插件